肺動脈性肺高血圧症（PAH）の世界市場（～2026年）

• 英文タイトル：Global Pulmonary Arterial Hypertension (PAH) Market Size, Status and Forecast 2020-2026

• レポートコード：MRC2-11QY04414
• 出版社/出版日：QYResearch / 2020年11月20日
※2024年版があります。お問い合わせください。
• レポート形態：英文、PDF、95ページ
• 納品方法：Eメール（納期：2~3日）
• 産業分類：ヘルスケア

• 販売価格（消費税別）

Single User	￥577,200 (USD3,900)	▷ お問い合わせ
Multi User	￥865,800 (USD5,850)	▷ お問い合わせ
Enterprise License	￥1,154,400 (USD7,800)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

レポート概要

当調査資料は肺動脈性肺高血圧症（PAH）のグローバル市場について調査・分析したレポートです。種類別（プロスタサイクリンおよびプロスタサイクリン類似体、SGC刺激剤、ERA、PDE-5）市場規模、用途別（病院、クリニック）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。
・調査範囲
・エグゼクティブサマリー
・企業別肺動脈性肺高血圧症（PAH）の競争状況、市場シェア
・世界の肺動脈性肺高血圧症（PAH）市場：種類別市場規模 2015年-2020年（プロスタサイクリンおよびプロスタサイクリン類似体、SGC刺激剤、ERA、PDE-5）
・世界の肺動脈性肺高血圧症（PAH）市場：種類別市場規模予測 2021年-2026年（プロスタサイクリンおよびプロスタサイクリン類似体、SGC刺激剤、ERA、PDE-5）
・世界の肺動脈性肺高血圧症（PAH）市場：用途別市場規模 2015年-2020年（病院、クリニック）
・世界の肺動脈性肺高血圧症（PAH）市場：用途別市場規模予測 2021年-2026年（病院、クリニック）
・北米の肺動脈性肺高血圧症（PAH）市場分析：米国、カナダ
・ヨーロッパの肺動脈性肺高血圧症（PAH）市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等
・アジアの肺動脈性肺高血圧症（PAH）市場分析：日本、中国、韓国、インド、オーストラリア、台湾等
・中南米の肺動脈性肺高血圧症（PAH）市場分析：メキシコ、ブラジル、アルゼンチン等
・中東・アフリカの肺動脈性肺高血圧症（PAH）市場分析：トルコ、サウジアラビア、UAE等
・企業情報（企業概要、製品概要、販売量、企業動向）
- 掲載企業（変更可能性あり）：Actelion、Gilead Sciences、United Therapeutics、GlaxoSmithKline、Pfizer、Bayer、Arena
・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場
・市場機会、課題、リスク、環境分析
・バリューチェーン、販売チャネル分析
・調査の結論

Market Analysis and Insights: Global Pulmonary Arterial Hypertension (PAH) Market
The global Pulmonary Arterial Hypertension (PAH) market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026.

Global Pulmonary Arterial Hypertension (PAH) Scope and Market Size
Pulmonary Arterial Hypertension (PAH) market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Pulmonary Arterial Hypertension (PAH) market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.

The key players covered in this study
Actelion
Gilead Sciences
United Therapeutics
GlaxoSmithKline
Pfizer
Bayer
Arena
…

Market segment by Type, the product can be split into
Prostacyclin and Prostacyclin Analogs
SGC Stimulators
ERA
PDE-5
Market segment by Application, split into
Hospital
Clinic

Market segment by Regions/Countries, this report covers
North America
Europe
China
Japan
Southeast Asia
India

レポート目次

1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Pulmonary Arterial Hypertension (PAH) Revenue
1.4 Market by Type
1.4.1 Global Pulmonary Arterial Hypertension (PAH) Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Prostacyclin and Prostacyclin Analogs
1.4.3 SGC Stimulators
1.4.4 ERA
1.4.5 PDE-5
1.5 Market by Application
1.5.1 Global Pulmonary Arterial Hypertension (PAH) Market Share by Application: 2020 VS 2026
1.5.2 Hospital
1.5.3 Clinic
1.6 Study Objectives
1.7 Years Considered

2 Global Growth Trends
2.1 Global Pulmonary Arterial Hypertension (PAH) Market Perspective (2015-2026)
2.2 Global Pulmonary Arterial Hypertension (PAH) Growth Trends by Regions
2.2.1 Pulmonary Arterial Hypertension (PAH) Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Pulmonary Arterial Hypertension (PAH) Historic Market Share by Regions (2015-2020)
2.2.3 Pulmonary Arterial Hypertension (PAH) Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Pulmonary Arterial Hypertension (PAH) Market Growth Strategy
2.3.6 Primary Interviews with Key Pulmonary Arterial Hypertension (PAH) Players (Opinion Leaders)

3 Competition Landscape by Key Players
3.1 Global Top Pulmonary Arterial Hypertension (PAH) Players by Market Size
3.1.1 Global Top Pulmonary Arterial Hypertension (PAH) Players by Revenue (2015-2020)
3.1.2 Global Pulmonary Arterial Hypertension (PAH) Revenue Market Share by Players (2015-2020)
3.1.3 Global Pulmonary Arterial Hypertension (PAH) Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Pulmonary Arterial Hypertension (PAH) Market Concentration Ratio
3.2.1 Global Pulmonary Arterial Hypertension (PAH) Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Pulmonary Arterial Hypertension (PAH) Revenue in 2019
3.3 Pulmonary Arterial Hypertension (PAH) Key Players Head office and Area Served
3.4 Key Players Pulmonary Arterial Hypertension (PAH) Product Solution and Service
3.5 Date of Enter into Pulmonary Arterial Hypertension (PAH) Market
3.6 Mergers & Acquisitions, Expansion Plans

4 Market Size by Type (2015-2026)
4.1 Global Pulmonary Arterial Hypertension (PAH) Historic Market Size by Type (2015-2020)
4.2 Global Pulmonary Arterial Hypertension (PAH) Forecasted Market Size by Type (2021-2026)

5 Market Size by Application (2015-2026)
5.1 Global Pulmonary Arterial Hypertension (PAH) Market Size by Application (2015-2020)
5.2 Global Pulmonary Arterial Hypertension (PAH) Forecasted Market Size by Application (2021-2026)

6 North America
6.1 North America Pulmonary Arterial Hypertension (PAH) Market Size (2015-2020)
6.2 Pulmonary Arterial Hypertension (PAH) Key Players in North America (2019-2020)
6.3 North America Pulmonary Arterial Hypertension (PAH) Market Size by Type (2015-2020)
6.4 North America Pulmonary Arterial Hypertension (PAH) Market Size by Application (2015-2020)

7 Europe
7.1 Europe Pulmonary Arterial Hypertension (PAH) Market Size (2015-2020)
7.2 Pulmonary Arterial Hypertension (PAH) Key Players in Europe (2019-2020)
7.3 Europe Pulmonary Arterial Hypertension (PAH) Market Size by Type (2015-2020)
7.4 Europe Pulmonary Arterial Hypertension (PAH) Market Size by Application (2015-2020)

8 China
8.1 China Pulmonary Arterial Hypertension (PAH) Market Size (2015-2020)
8.2 Pulmonary Arterial Hypertension (PAH) Key Players in China (2019-2020)
8.3 China Pulmonary Arterial Hypertension (PAH) Market Size by Type (2015-2020)
8.4 China Pulmonary Arterial Hypertension (PAH) Market Size by Application (2015-2020)

9 Japan
9.1 Japan Pulmonary Arterial Hypertension (PAH) Market Size (2015-2020)
9.2 Pulmonary Arterial Hypertension (PAH) Key Players in Japan (2019-2020)
9.3 Japan Pulmonary Arterial Hypertension (PAH) Market Size by Type (2015-2020)
9.4 Japan Pulmonary Arterial Hypertension (PAH) Market Size by Application (2015-2020)

10 Southeast Asia
10.1 Southeast Asia Pulmonary Arterial Hypertension (PAH) Market Size (2015-2020)
10.2 Pulmonary Arterial Hypertension (PAH) Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Pulmonary Arterial Hypertension (PAH) Market Size by Type (2015-2020)
10.4 Southeast Asia Pulmonary Arterial Hypertension (PAH) Market Size by Application (2015-2020)

11 India
11.1 India Pulmonary Arterial Hypertension (PAH) Market Size (2015-2020)
11.2 Pulmonary Arterial Hypertension (PAH) Key Players in India (2019-2020)
11.3 India Pulmonary Arterial Hypertension (PAH) Market Size by Type (2015-2020)
11.4 India Pulmonary Arterial Hypertension (PAH) Market Size by Application (2015-2020)

12 Central & South America
12.1 Central & South America Pulmonary Arterial Hypertension (PAH) Market Size (2015-2020)
12.2 Pulmonary Arterial Hypertension (PAH) Key Players in Central & South America (2019-2020)
12.3 Central & South America Pulmonary Arterial Hypertension (PAH) Market Size by Type (2015-2020)
12.4 Central & South America Pulmonary Arterial Hypertension (PAH) Market Size by Application (2015-2020)

13 Key Players Profiles
13.1 Actelion
13.1.1 Actelion Company Details
13.1.2 Actelion Business Overview
13.1.3 Actelion Pulmonary Arterial Hypertension (PAH) Introduction
13.1.4 Actelion Revenue in Pulmonary Arterial Hypertension (PAH) Business (2015-2020))
13.1.5 Actelion Recent Development
13.2 Gilead Sciences
13.2.1 Gilead Sciences Company Details
13.2.2 Gilead Sciences Business Overview
13.2.3 Gilead Sciences Pulmonary Arterial Hypertension (PAH) Introduction
13.2.4 Gilead Sciences Revenue in Pulmonary Arterial Hypertension (PAH) Business (2015-2020)
13.2.5 Gilead Sciences Recent Development
13.3 United Therapeutics
13.3.1 United Therapeutics Company Details
13.3.2 United Therapeutics Business Overview
13.3.3 United Therapeutics Pulmonary Arterial Hypertension (PAH) Introduction
13.3.4 United Therapeutics Revenue in Pulmonary Arterial Hypertension (PAH) Business (2015-2020)
13.3.5 United Therapeutics Recent Development
13.4 GlaxoSmithKline
13.4.1 GlaxoSmithKline Company Details
13.4.2 GlaxoSmithKline Business Overview
13.4.3 GlaxoSmithKline Pulmonary Arterial Hypertension (PAH) Introduction
13.4.4 GlaxoSmithKline Revenue in Pulmonary Arterial Hypertension (PAH) Business (2015-2020)
13.4.5 GlaxoSmithKline Recent Development
13.5 Pfizer
13.5.1 Pfizer Company Details
13.5.2 Pfizer Business Overview
13.5.3 Pfizer Pulmonary Arterial Hypertension (PAH) Introduction
13.5.4 Pfizer Revenue in Pulmonary Arterial Hypertension (PAH) Business (2015-2020)
13.5.5 Pfizer Recent Development
13.6 Bayer
13.6.1 Bayer Company Details
13.6.2 Bayer Business Overview
13.6.3 Bayer Pulmonary Arterial Hypertension (PAH) Introduction
13.6.4 Bayer Revenue in Pulmonary Arterial Hypertension (PAH) Business (2015-2020)
13.6.5 Bayer Recent Development
13.7 Arena
13.7.1 Arena Company Details
13.7.2 Arena Business Overview
13.7.3 Arena Pulmonary Arterial Hypertension (PAH) Introduction
13.7.4 Arena Revenue in Pulmonary Arterial Hypertension (PAH) Business (2015-2020)
13.7.5 Arena Recent Development

14 Analyst’s Viewpoints/Conclusions

15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details

List of Tables
Table 1. Pulmonary Arterial Hypertension (PAH) Key Market Segments
Table 2. Key Players Covered: Ranking by Pulmonary Arterial Hypertension (PAH) Revenue
Table 3. Ranking of Global Top Pulmonary Arterial Hypertension (PAH) Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Pulmonary Arterial Hypertension (PAH) Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of Prostacyclin and Prostacyclin Analogs
Table 6. Key Players of SGC Stimulators
Table 7. Key Players of ERA
Table 8. Key Players of PDE-5
Table 9. Global Pulmonary Arterial Hypertension (PAH) Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 10. Global Pulmonary Arterial Hypertension (PAH) Market Size by Regions (US$ Million): 2020 VS 2026
Table 11. Global Pulmonary Arterial Hypertension (PAH) Market Size by Regions (2015-2020) (US$ Million)
Table 12. Global Pulmonary Arterial Hypertension (PAH) Market Share by Regions (2015-2020)
Table 13. Global Pulmonary Arterial Hypertension (PAH) Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 14. Global Pulmonary Arterial Hypertension (PAH) Market Share by Regions (2021-2026)
Table 15. Market Top Trends
Table 16. Key Drivers: Impact Analysis
Table 17. Key Challenges
Table 18. Pulmonary Arterial Hypertension (PAH) Market Growth Strategy
Table 19. Main Points Interviewed from Key Pulmonary Arterial Hypertension (PAH) Players
Table 20. Global Pulmonary Arterial Hypertension (PAH) Revenue by Players (2015-2020) (Million US$)
Table 21. Global Pulmonary Arterial Hypertension (PAH) Market Share by Players (2015-2020)
Table 22. Global Top Pulmonary Arterial Hypertension (PAH) Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Pulmonary Arterial Hypertension (PAH) as of 2019)
Table 23. Global Pulmonary Arterial Hypertension (PAH) by Players Market Concentration Ratio (CR5 and HHI)
Table 24. Key Players Headquarters and Area Served
Table 25. Key Players Pulmonary Arterial Hypertension (PAH) Product Solution and Service
Table 26. Date of Enter into Pulmonary Arterial Hypertension (PAH) Market
Table 27. Mergers & Acquisitions, Expansion Plans
Table 28. Global Pulmonary Arterial Hypertension (PAH) Market Size by Type (2015-2020) (Million US$)
Table 29. Global Pulmonary Arterial Hypertension (PAH) Market Size Share by Type (2015-2020)
Table 30. Global Pulmonary Arterial Hypertension (PAH) Revenue Market Share by Type (2021-2026)
Table 31. Global Pulmonary Arterial Hypertension (PAH) Market Size Share by Application (2015-2020)
Table 32. Global Pulmonary Arterial Hypertension (PAH) Market Size by Application (2015-2020) (Million US$)
Table 33. Global Pulmonary Arterial Hypertension (PAH) Market Size Share by Application (2021-2026)
Table 34. North America Key Players Pulmonary Arterial Hypertension (PAH) Revenue (2019-2020) (Million US$)
Table 35. North America Key Players Pulmonary Arterial Hypertension (PAH) Market Share (2019-2020)
Table 36. North America Pulmonary Arterial Hypertension (PAH) Market Size by Type (2015-2020) (Million US$)
Table 37. North America Pulmonary Arterial Hypertension (PAH) Market Share by Type (2015-2020)
Table 38. North America Pulmonary Arterial Hypertension (PAH) Market Size by Application (2015-2020) (Million US$)
Table 39. North America Pulmonary Arterial Hypertension (PAH) Market Share by Application (2015-2020)
Table 40. Europe Key Players Pulmonary Arterial Hypertension (PAH) Revenue (2019-2020) (Million US$)
Table 41. Europe Key Players Pulmonary Arterial Hypertension (PAH) Market Share (2019-2020)
Table 42. Europe Pulmonary Arterial Hypertension (PAH) Market Size by Type (2015-2020) (Million US$)
Table 43. Europe Pulmonary Arterial Hypertension (PAH) Market Share by Type (2015-2020)
Table 44. Europe Pulmonary Arterial Hypertension (PAH) Market Size by Application (2015-2020) (Million US$)
Table 45. Europe Pulmonary Arterial Hypertension (PAH) Market Share by Application (2015-2020)
Table 46. China Key Players Pulmonary Arterial Hypertension (PAH) Revenue (2019-2020) (Million US$)
Table 47. China Key Players Pulmonary Arterial Hypertension (PAH) Market Share (2019-2020)
Table 48. China Pulmonary Arterial Hypertension (PAH) Market Size by Type (2015-2020) (Million US$)
Table 49. China Pulmonary Arterial Hypertension (PAH) Market Share by Type (2015-2020)
Table 50. China Pulmonary Arterial Hypertension (PAH) Market Size by Application (2015-2020) (Million US$)
Table 51. China Pulmonary Arterial Hypertension (PAH) Market Share by Application (2015-2020)
Table 52. Japan Key Players Pulmonary Arterial Hypertension (PAH) Revenue (2019-2020) (Million US$)
Table 53. Japan Key Players Pulmonary Arterial Hypertension (PAH) Market Share (2019-2020)
Table 54. Japan Pulmonary Arterial Hypertension (PAH) Market Size by Type (2015-2020) (Million US$)
Table 55. Japan Pulmonary Arterial Hypertension (PAH) Market Share by Type (2015-2020)
Table 56. Japan Pulmonary Arterial Hypertension (PAH) Market Size by Application (2015-2020) (Million US$)
Table 57. Japan Pulmonary Arterial Hypertension (PAH) Market Share by Application (2015-2020)
Table 58. Southeast Asia Key Players Pulmonary Arterial Hypertension (PAH) Revenue (2019-2020) (Million US$)
Table 59. Southeast Asia Key Players Pulmonary Arterial Hypertension (PAH) Market Share (2019-2020)
Table 60. Southeast Asia Pulmonary Arterial Hypertension (PAH) Market Size by Type (2015-2020) (Million US$)
Table 61. Southeast Asia Pulmonary Arterial Hypertension (PAH) Market Share by Type (2015-2020)
Table 62. Southeast Asia Pulmonary Arterial Hypertension (PAH) Market Size by Application (2015-2020) (Million US$)
Table 63. Southeast Asia Pulmonary Arterial Hypertension (PAH) Market Share by Application (2015-2020)
Table 64. India Key Players Pulmonary Arterial Hypertension (PAH) Revenue (2019-2020) (Million US$)
Table 65. India Key Players Pulmonary Arterial Hypertension (PAH) Market Share (2019-2020)
Table 66. India Pulmonary Arterial Hypertension (PAH) Market Size by Type (2015-2020) (Million US$)
Table 67. India Pulmonary Arterial Hypertension (PAH) Market Share by Type (2015-2020)
Table 68. India Pulmonary Arterial Hypertension (PAH) Market Size by Application (2015-2020) (Million US$)
Table 69. India Pulmonary Arterial Hypertension (PAH) Market Share by Application (2015-2020)
Table 70. Central & South America Key Players Pulmonary Arterial Hypertension (PAH) Revenue (2019-2020) (Million US$)
Table 71. Central & South America Key Players Pulmonary Arterial Hypertension (PAH) Market Share (2019-2020)
Table 72. Central & South America Pulmonary Arterial Hypertension (PAH) Market Size by Type (2015-2020) (Million US$)
Table 73. Central & South America Pulmonary Arterial Hypertension (PAH) Market Share by Type (2015-2020)
Table 74. Central & South America Pulmonary Arterial Hypertension (PAH) Market Size by Application (2015-2020) (Million US$)
Table 75. Central & South America Pulmonary Arterial Hypertension (PAH) Market Share by Application (2015-2020)
Table 76. Actelion Company Details
Table 77. Actelion Business Overview
Table 78. Actelion Product
Table 79. Actelion Revenue in Pulmonary Arterial Hypertension (PAH) Business (2015-2020) (Million US$)
Table 80. Actelion Recent Development
Table 81. Gilead Sciences Company Details
Table 82. Gilead Sciences Business Overview
Table 83. Gilead Sciences Product
Table 84. Gilead Sciences Revenue in Pulmonary Arterial Hypertension (PAH) Business (2015-2020) (Million US$)
Table 85. Gilead Sciences Recent Development
Table 86. United Therapeutics Company Details
Table 87. United Therapeutics Business Overview
Table 88. United Therapeutics Product
Table 89. United Therapeutics Revenue in Pulmonary Arterial Hypertension (PAH) Business (2015-2020) (Million US$)
Table 90. United Therapeutics Recent Development
Table 91. GlaxoSmithKline Company Details
Table 92. GlaxoSmithKline Business Overview
Table 93. GlaxoSmithKline Product
Table 94. GlaxoSmithKline Revenue in Pulmonary Arterial Hypertension (PAH) Business (2015-2020) (Million US$)
Table 95. GlaxoSmithKline Recent Development
Table 96. Pfizer Company Details
Table 97. Pfizer Business Overview
Table 98. Pfizer Product
Table 99. Pfizer Revenue in Pulmonary Arterial Hypertension (PAH) Business (2015-2020) (Million US$)
Table 100. Pfizer Recent Development
Table 101. Bayer Company Details
Table 102. Bayer Business Overview
Table 103. Bayer Product
Table 104. Bayer Revenue in Pulmonary Arterial Hypertension (PAH) Business (2015-2020) (Million US$)
Table 105. Bayer Recent Development
Table 106. Arena Company Details
Table 107. Arena Business Overview
Table 108. Arena Product
Table 109. Arena Revenue in Pulmonary Arterial Hypertension (PAH) Business (2015-2020) (Million US$)
Table 110. Arena Recent Development
Table 111. Research Programs/Design for This Report
Table 112. Key Data Information from Secondary Sources
Table 113. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Pulmonary Arterial Hypertension (PAH) Market Share by Type: 2020 VS 2026
Figure 2. Prostacyclin and Prostacyclin Analogs Features
Figure 3. SGC Stimulators Features
Figure 4. ERA Features
Figure 5. PDE-5 Features
Figure 6. Global Pulmonary Arterial Hypertension (PAH) Market Share by Application: 2020 VS 2026
Figure 7. Hospital Case Studies
Figure 8. Clinic Case Studies
Figure 9. Pulmonary Arterial Hypertension (PAH) Report Years Considered
Figure 10. Global Pulmonary Arterial Hypertension (PAH) Market Size YoY Growth 2015-2026 (US$ Million)
Figure 11. Global Pulmonary Arterial Hypertension (PAH) Market Share by Regions: 2020 VS 2026
Figure 12. Global Pulmonary Arterial Hypertension (PAH) Market Share by Regions (2021-2026)
Figure 13. Porter's Five Forces Analysis
Figure 14. Global Pulmonary Arterial Hypertension (PAH) Market Share by Players in 2019
Figure 15. Global Top Pulmonary Arterial Hypertension (PAH) Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Pulmonary Arterial Hypertension (PAH) as of 2019
Figure 16. The Top 10 and 5 Players Market Share by Pulmonary Arterial Hypertension (PAH) Revenue in 2019
Figure 17. North America Pulmonary Arterial Hypertension (PAH) Market Size YoY Growth (2015-2020) (Million US$)
Figure 18. Europe Pulmonary Arterial Hypertension (PAH) Market Size YoY Growth (2015-2020) (Million US$)
Figure 19. China Pulmonary Arterial Hypertension (PAH) Market Size YoY Growth (2015-2020) (Million US$)
Figure 20. Japan Pulmonary Arterial Hypertension (PAH) Market Size YoY Growth (2015-2020) (Million US$)
Figure 21. Southeast Asia Pulmonary Arterial Hypertension (PAH) Market Size YoY Growth (2015-2020) (Million US$)
Figure 22. India Pulmonary Arterial Hypertension (PAH) Market Size YoY Growth (2015-2020) (Million US$)
Figure 23. Central & South America Pulmonary Arterial Hypertension (PAH) Market Size YoY Growth (2015-2020) (Million US$)
Figure 24. Bottom-up and Top-down Approaches for This Report
Figure 25. Data Triangulation
Figure 26. Key Executives Interviewed

以下、関連資料のご紹介

慢性血栓塞栓性肺高血圧症（CTEPH）の世界市場（～2026年）

Global Chronic Thromboembolic Pulmonary Hypertension Market Size, Status and Forecast 2020-2026
MRC2-11QY11373 2020年11月25日 99Pages
当調査資料は慢性血栓塞栓性肺高血圧症（CTEPH）のグローバル市場について調査・分析したレポートです。種類別（経胸壁心エコー検査（TTE）、換気灌流（V/Q）スキャン、肺血管造影、心臓カテーテル検査、コンピューター断層撮影（CT）肺血管造影、その他）市場規模、用途別（病院、外来手術センター、その他）...

3D動脈スピンラベリング（3D ASL）の世界市場（～2026年）

Global 3D Arterial Spin Labeling (3D ASL) Market Size, Status and Forecast 2020-2026
MRC2-11QY13519 2020年11月30日 93Pages
当調査資料は3D動脈スピンラベリング（3D ASL）のグローバル市場について調査・分析したレポートです。種類別（CASL、PASL）市場規模、用途別（腫瘍、脳血管障害、神経変性疾患、パーキンソン病）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア...

肺ドラッグデリバリーシステム（PDDS）の世界市場（～2026年）

Global Pulmonary Drug Delivery System (PDDS) Market Size, Status and Forecast 2020-2026
MRC2-11QY04415 2020年11月20日 94Pages
当調査資料は肺ドラッグデリバリーシステム（PDDS）のグローバル市場について調査・分析したレポートです。種類別（エアロゾル、エアロゾル吸入剤）市場規模、用途別（喘息、慢性気管支炎、肺感染症、閉塞性肺気腫、その他）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、...

特発性肺線維症（IPF）の世界市場（～2026年）

Global Idiopathic Pulmonary Fibrosis Market Size, Status and Forecast 2020-2026
MRC2-11QY12298 2020年11月25日 95Pages
当調査資料は特発性肺線維症（IPF）のグローバル市場について調査・分析したレポートです。種類別（全身性コルチコステロイド、免疫抑制薬、チロシンキナーゼ阻害剤、抗線維化剤）市場規模、用途別（病院、クリニック、外来手術センター、学術・研究機関）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フ...

慢性閉塞性肺疾患（COPD）の世界市場（～2026年）

Global Chronic Obstructive Pulmonary Disease Market Size, Status and Forecast 2020-2026
MRC2-11QY11371 2020年11月25日 90Pages
当調査資料は慢性閉塞性肺疾患（COPD）のグローバル市場について調査・分析したレポートです。種類別（気管支拡張薬、糖質コルチコイド、その他）市場規模、用途別（予防、診断、治療）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、イ...

末梢動脈疾患（PAD）薬の世界市場（～2026年）

Global Peripheral Arterial Disease (PAD) Drugs Market Size, Status and Forecast 2020-2026
MRC2-11QY04220 2020年11月20日 90Pages
当調査資料は末梢動脈疾患（PAD）薬のグローバル市場について調査・分析したレポートです。種類別（クロピドグレル（プラビックス）、プラスグレル（効率的）、チカグレロル（ブリリンタ）、ボラパクサー（帯状）、その他）市場規模、用途別（病院、診療所、その他）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、...

特発性頭蓋内圧亢進症治療薬の世界市場（～2026年）

Global Idiopathic Intracranial Hypertension Therapeutics Market Size, Status and Forecast 2020-2026
MRC2-11QY12296 2020年11月25日 98Pages
当調査資料は特発性頭蓋内圧亢進症治療薬のグローバル市場について調査・分析したレポートです。種類別（アセタゾラミド、フロセミド、トピラマート、オクトレオチド）市場規模、用途別（病院薬局、小売薬局、その他）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、ア...

高血圧治療薬の世界市場（～2026年）

Global Hypertension Drugs Market Insights and Forecast to 2026
MRC2-11QY01518 2020年11月20日 117Pages
当調査資料は高血圧治療薬のグローバル市場について調査・分析したレポートです。種類別（カルシウム拮抗薬、利尿薬、ベータ遮断薬、血管拡張薬、アンジオテンシン変換酵素阻害薬、アルファ遮断薬、アンジオテンシン受容体遮断薬、レニン阻害薬）市場規模、用途別（病院、診療所、その他）市場規模、地域別（北米、米国、カ...

特発性頭蓋内圧亢進症治療の世界市場（～2026年）

Global Idiopathic Intracranial Hypertension Treatment Market Size, Status and Forecast 2020-2026
MRC2-11QY12297 2020年11月25日 129Pages
当調査資料は特発性頭蓋内圧亢進症治療のグローバル市場について調査・分析したレポートです。種類別（アセタゾラミド、メタゾラミド、フロセミド、トピラマート、その他）市場規模、用途別（病院、クリニック、外来手術センター）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア...

末梢動脈疾患（PAD）治療薬の世界市場（～2026年）

Global Peripheral Arterial Disease (PAD) Therapeutics Market Size, Status and Forecast 2020-2026
MRC2-11QY04221 2020年11月20日 94Pages
当調査資料は末梢動脈疾患（PAD）治療薬のグローバル市場について調査・分析したレポートです。種類別（抗血小板薬、二重抗血小板療法薬、その他）市場規模、用途別（病院、診療所、その他）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国...

慢性血栓塞栓性肺高血圧症（CTEPH）の世界市場（～2026年） Chronic thromboembolic pulmonary hypertension is observed to be one of the leading causes of severe pulmonary hypertension. It is a type of clinical condition in which pulmonary vascular resistance increases giving rise to pulmonary hypertension and progressive heart failure. According to World Heal…
3D動脈スピンラベリング（3D ASL）の世界市場（～2026年） Market Analysis and Insights: Global 3D Arterial Spin Labeling (3D ASL) Market The global 3D Arterial Spin Labeling (3D ASL) market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global 3D Arterial Spin Labeling (3D ASL) Scope and …
特発性頭蓋内圧亢進症治療薬の世界市場（～2026年） A drug used to treat idiopathic intracranial hypertension. Market Analysis and Insights: Global Idiopathic Intracranial Hypertension Therapeutics Market The global Idiopathic Intracranial Hypertension Therapeutics market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020,…
末梢動脈疾患（PAD）薬の世界市場（～2026年） Market Analysis and Insights: Global Peripheral Arterial Disease (PAD) Drugs Market The global Peripheral Arterial Disease (PAD) Drugs market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Peripheral Arterial Disease (PAD) D…
特発性頭蓋内圧亢進症治療の世界市場（～2026年） Idiopathic intracranial hypertension is characterized by a buildup of the cerebrospinal fluid causing increase in the blood volume in vessels surrounding the brain and increase in brain swelling. The increase in salt intake causes water retention in the body together with fat adding on to the calori…